益佰製藥(600594.SH):長安製藥擬6.03億元建設美安科技新城新廠建設項目
格隆匯1月8日丨益佰製藥(600594.SH)公佈,公司全資子公司海南長安國際製藥有限公司(以下簡稱“長安製藥”)現有產能已無法滿足公司主要產品獨家原研一類新藥、第三代鉑類抗腫瘤藥注射用洛鉑日益增長的市場需求。
根據公司戰略發展規劃,為解決發展瓶頸,同時為提升公司大力發展包括抗腫瘤藥在內的化學藥的生產能力,提高公司產品的研發生產能力,擴大公司產品規模,以提升公司的綜合競爭力,長安製藥擬在海口市美安科技新城內投資建設“美安科技新城新廠建設項目”,該項目建成後將從事相關產品的生產經營活動,未來將成為一個滿足公司發展需求的產品研發生產基地。該項目固定資產總投資預計為人民幣6.03億元,項目所需資金為銀行貸款及自有資金。
項目規劃土地使用面積為5.33萬平方米(合80畝),建築總面積為7.28萬平方米。項目建設內容包括建設一條滿足國際認證標準、國內銷售需求的年產700萬支凍乾粉針劑生產線和一條生產相關產品所需原料的生產線及相應質量的公用工程配套設施,以及用於未來新品種引進的研發、中試和生產場地。打造一個滿足公司發展需求的產品研發生產基地。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.